parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in astrocytes (323 nCPM)	1.00
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 26	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 9377

GRAMD1C in dopamine neurons, braak+0.49 (p 0.186) → +0.04 (p 0.909)receipt 9385
GRAMD1C in astrocytes, braak-0.45 (p 0.222) → +0.28 (p 0.467)receipt 9384

receipt 9385: GRAMD1C in dopamine neurons, braak

power: full sample +0.25 (p 0.323, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.24 (p 0.346, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.328, n 18). could be the mix.
skeptic: leave-one-out range +0.14 to +0.34, sign flips 0; without severely affected donors +0.25 (p 0.323, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GRAMD1C in dopamine neurons.

case closed: nothing better to follow up.

receipt 9384: GRAMD1C in astrocytes, braak

power: full sample +0.01 (p 0.976, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.07 (p 0.781, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.22 (p 0.389, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.10, sign flips 8; without severely affected donors +0.01 (p 0.976, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GRAMD1C in astrocytes.

case closed: nothing better to follow up.

loading the receipts